UKIDS

  • Research type

    Research Study

  • Full title

    UK Imaging Diabetes Study Seeing Diabetes Clearly (UKIDS)

  • IRAS ID

    270740

  • Contact name

    Rajarshi Banerjee

  • Contact email

    rajarshi.banerjee@perspectum.com

  • Sponsor organisation

    Perspectum Diagnostics Ltd.

  • Duration of Study in the UK

    12 years, 0 months, 1 days

  • Research summary

    This will be a prospective, observational, cohort study to evaluate if imaging abdominal organs could help improve clinical care by accurately identifying complications of type 2 diabetes (T2D). Participants with T2D and concurrent diabetic retinopathy will be recruited from Moorfields Hospital NHS Foundation Trust in London. Participants will be treated and assessed in line with normal clinical care.

    Type 2 diabetes often leads to more complicated diseases. People with T2D could also develop eye, liver disease, chronic kidney disease and cardiovascular disease. In the UK the 3.3 million people suffer from T2D, with heath care costs of £8.8 billion every year mostly as a result of disease complications. The method of diagnosing T2D is by measuring the glucose level in blood, whilst other blood and urine tests can diagnose the associated diseases in other organs. However, these tests do not provide complete information of effects on organs associated with T2D and its complications.

    Metformin is the first line of treatment for T2D. Newer drugs, like Liraglutide and Semaglutide, have beneficial effects on T2D complications. Unfortunately, these newer drugs cost far more than Metformin, so prescribing them to everyone with type 2 diabetes is not possible for the NHS. There is a need to find a way to find more specific tests that help personalise T2D care for the patient.

    The purpose of this study is to discover whether introducing a specialist Magnetic Resonance Imaging method can aid in earlier and more accurate diagnosis of complications for T2D. The MRI method will image and provide quantitative metrics for the kidneys, liver, pancreas, spleen and aorta, as well as body composition. We wish to evaluate whether this method can improve clinical care for patients, by monitoring the health of other vital organs and improving overall long-term health of the patient.

  • REC name

    West Midlands - Solihull Research Ethics Committee

  • REC reference

    20/WM/0007

  • Date of REC Opinion

    16 Mar 2020

  • REC opinion

    Further Information Favourable Opinion